[1] Beato M. Gene regulation by steroid hormones. Cell, 1989, 56(3): 335-344.
[2] Menasce LP, White GR, Harrison CJ, Boyle JM. Local-ization of the estrogen receptor locus (ESR) to chromo-some 6q25.1 by FISH and a simple post-FISH banding technique. Genomics, 1993, 17(1): 263-265.
[3] Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, Nolan C, Coombes RC. Estrogen and proges-terone receptors in the normal female breast. Cancer Res, 1991, 51(7): 1817-1822.
[4] Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE. Mapping of ER gene CpG island methylation-specific polymerase chain reac-tion. Cancer Res, 1998, 58(12): 2515-2519.
[5] Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res, 1994, 54(10): 2552-2555.
[6] Zhao L, Wang L, Jin F, Ma W, Ren J, Wen X, He M, Sun M, Tang H, Wei M. Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a fre-quent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat, 2009, 117(2): 253-259.
[7] Ferguson AT, Lapidus RG, Davidson NE. Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. Oncogene, 1998, 17(5): 577-583.
[8] Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE. Transcriptional ac-tivation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res, 2000, 60(24): 6890-6894.
[9] Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen recep-tor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther, 2003, 2(5): 552-556.
[10] Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Over-expression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estro-gen receptor alpha. Int J Cancer, 2003, 107(3): 353-358.
[11] Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res, 2009, 15(9): 3163-3171.
[12] Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a com-plex at replication foci. Nat Genet, 2000, 25(3): 269-277.
[13] El-Osta A, Wolffe AP. DNA methylation and histone deace-tylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr, 2000, 9(1-2): 63-75.
[14] Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA me-thylation to histone methylation. J Biol Chem, 2003, 278(6): 4035-4040.
[15] Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol, 2005, 19(7): 1740-1751.
[16] Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen re-ceptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat, 2003, 81(3): 177-186.
[17] Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, di Gh, Shen ZZ, Shao ZM. ER alpha negative breast cancer cells re-store response to endocrine therapy by combination treat-ment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol, 2008, 134(8): 883-890.
[18] Keaveney M, Klug J, Dawson MT, Nestor PV, Neilan JG, Forde RC, Gannon F. Evidence for a previously unidenti-fied upstream exon in the human oestrogen receptor gene. J Mol Endocrinol, 1991, 6(1): 111-115.
[19] Piva R, Bianchi N, Aguiari GL, Gambari R, Del SL. Se-quencing of an RNA transcript of the human estrogen re-ceptor gene: evidence for a new transcriptional event. J Steroid Biochem Mol Biol, 1993, 46(5): 531-538.
[20] Grandien KF, Berkenstam A, Nilsson S, Gustafsson JA. Localization of DNase I hypersensitive sites in the human oestrogen receptor gene correlates with the transcriptional activity of two differentially used promoters. J Mol Endocrinol, 1993, 10(3): 269-277.
[21] Hayashi S, Imai K, Suga K, Kurihara T, Higashi Y, Na-kachi K. Two promoters in expression of estrogen receptor messenger RNA in human breast cancer. Carcinogenesis, 1997, 18(3): 459-464.
[22] Tang Z, Treilleux I, Brown M. A transcriptional enhancer required for the differential expression of the human es-trogen receptor in breast cancers. Mol Cell Biol, 1997, 17(3): 1274-1280.
[23] Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol, 2004, 24(19): 8681-8690.
[24] Madureira PA, Varshochi R, Constantinidou D, Francis RE, Coombes RC, Yao KM, Lam EW. The Forkhead box M1 protein regulates the transcription of the estrogen re-ceptor alpha in breast cancer cells. J Biol Chem, 2006, 281(35): 25167-25176.
[25] Deconinck EC, Mcpherson LA, Weigel RJ. Transcrip-tional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol, 1995, 15(4): 2191-2196.
[26] Mcpherson LA, Baichwal VR, Weigel RJ. Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci USA, 1997, 94(9): 4342-4347.
[27] Woodfield GW, Horan AD, Chen Y, Weigel RJ. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res, 2007, 67(18): 8439-8443.
[28] Woodfield GW, Hitchler MJ, Chen Y, Domann FE, Weigel RJ. Interaction of TFAP2C with the estrogen re-ceptor-alpha promoter is controlled by chromatin structure. Clin Cancer Res, 2009, 15(11): 3672-3679.
[29] Tanimoto K, Eguchi H, Yoshida T, Hajiro-Nakanishi K, Hayashi S. Regulation of estrogen receptor alpha gene mediated by promoter B responsible for its enhanced ex-pressionin human breast cancer. Nucleic Acids Res, 1999, 27(3): 903-909.
[30] Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. Regulation of estrogen receptor- alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol, 2004, 180(3): 497-504.
[31] Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M, Clarke R. Human X-box binding protein-1 confers both estrogen in-dependence and antiestrogen resistance in breast cancer cell lines. FASEB J, 2007, 21(14): 4013-4027.
[32] Adams BD, Furneaux H, White BA. The mi-cro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol, 2007, 21(5): 1132-1147.
[33] Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 Expression is down-regulated in estrogen recep-tor alpha-positive human breast cancer. Cancer Res, 2008, 68(13): 5004-5008.
[34] Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates es-trogen receptor alpha and is associated with t moxifen resistance in breast cancer. J Biol Chem, 2008, 283(45): 31079-31086.
[35] Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, Burghardt R, Safe S. The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol, 2003, 23(6): 1843-1855.
[36] Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA, 1999, 96(5): 1858-1862.
[37] Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell, 2003, 11(3): 695-707.
[38] Luo M, Koh M, Feng J, Wu Q, Melamed P. Cross talk in hormonally regulated gene transcription through induction of estrogen receptor ubiquitylation. Mol Cell Biol, 2005, 25(16): 7386-7398.
[39] Chu I, Arnaout A, Loiseau S, Sun J, Seth A, Mcmahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, Slingerland JM. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest, 2007, 117(8): 2205-2215.
[40] Shao W, Keeton EK, Mcdonnell DP, Brown M. Coactiva-tor AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci USA, 2004, 101(32): 11599-11604.
[41] Nakajima A, Maruyama S, Bohgaki M, Miyajima N, Tsu-kiyama T, Sakuragi N, Hatakeyama S. Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP. Biochem Biophys Res Commun, 2007, 357(1): 245-251.
[42] Tateishi Y, Kawabe Y, Chiba T, Murata S, Ichikawa K, Mu-rayama A, Tanaka K, Baba T, Kato S, Yanagisawa J. Ligand- dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J, 2004, 23(24): 4813-4823.
[43] Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, Cavailles V. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res, 2007, 67(11): 5513-5521.
[44] Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D. Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol, 2007, 21(10): 2427-2439.
[45] Park S, Song J, Joe CO, Shin I. Akt stabilizes estrogen receptor alpha with the concomitant reduction in its tran-scriptional activity. Cell Signal, 2008, 20(7): 1368-1374.
[46] Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell, 2006, 21(2): 295-305.
[47] Callige M, Kieffer I, Richard-Foy H. CSN5/Jab1 is in-volved in ligand-dependent degradation of estrogen re-ceptor {alpha} by the proteasome. Mol Cell Biol, 2005, 25(11): 4349-4358.
[48] Henrich LM, Smith JA, Kitt D, Errington TM, Nguyen B, Traish AM, Lannigan DA. Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Mol Cell Biol, 2003, 23(17): 5979-5988.
[49] Eakin CM, Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiq-uitin ligase. Proc Natl Acad Sci USA, 2007, 104(14): 5794-5799.
[50] Li L, Li Z, Howley PM, Sacks DB. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J Biol Chem, 2006, 281(4): 1978-1985.
[51] Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiprolif-erative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol Endocrinol, 2003, 17(3): 356-365.
[52] Subramanian K, Jia D, Kapoor-Vazirani P, Powell DR, Collins RE, Sharma D, Peng J, Cheng X, Vertino PM. Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell, 2008, 30(3): 336-347. |